A Phase II Study of S-1 for Previously Untreated Elderly Patients with Advanced Non-Small Cell Lung Cancer
| Autor: | Mikio Oka, Minoru Fukuda, Takeshi Kitazaki, Seiji Nagashima, Kazuhiro Tsukamoto, Takashi Kasai, Takaya Ikeda, Hirofumi Nakano, Hiroshi Takatani, Katsumi Nakatomi, Hiroyuki Yamaguchi, Shigeru Kohno, Yoichi Nakamura |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Male
0301 basic medicine Oncology Antimetabolites Antineoplastic medicine.medical_specialty Lung Neoplasms Neutropenia Vomiting Anemia Nausea medicine.medical_treatment Phases of clinical research Gastroenterology Drug Administration Schedule 03 medical and health sciences 0302 clinical medicine Carcinoma Non-Small-Cell Lung Internal medicine Drug Discovery Humans Medicine Pharmacology (medical) Lung cancer Aged Tegafur Aged 80 and over Pharmacology Chemotherapy Performance status business.industry General Medicine medicine.disease Drug Combinations Oxonic Acid Treatment Outcome 030104 developmental biology Infectious Diseases 030220 oncology & carcinogenesis Female medicine.symptom business Febrile neutropenia |
| Zdroj: | Chemotherapy. 61:93-98 |
| ISSN: | 1421-9794 0009-3157 |
| DOI: | 10.1159/000441486 |
| Popis: | Background: S-1, a novel oral fluoropyrimidine, is active in the treatment of non-small cell lung cancer (NSCLC). However, data on S-1 for elderly patients with NSCLC are insufficient. Methods: Eligibility criteria were no prior chemotherapy, stage IIIB or IV NSCLC, performance status 0-1, age >70 years, and adequate hematological, hepatic, and renal functions. Patients received S-1 (40 mg/m2 twice a day) for 28 consecutive days. This schedule was repeated every 6 weeks. The primary end point was the tumor response rate. Results: Thirty-two patients were enrolled and 31 patients were evaluable for response. The patients' median age was 80 years (range: 71-88). The response rate was 22.6% (95% CI: 11-38). Neutropenia, anemia, thrombocytopenia, febrile neutropenia, and diarrhea of grade ≥3 occurred in 6, 6, 10, 3, and 3%, respectively. Conclusions: In elderly patients with previously untreated advanced NSCLC, S-1 appears to be well tolerated and demonstrates encouraging activity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|